One of the companies which could be worth tracking at this point in time is The Trendlines Group Ltd (OTCMKTS:TRNLY) following a key new development in relation to its portfolio company liberDi Ltd. It was announced yesterday by liberDi that it had been awarded the coveted regulatory approval for its Digital Dialysis Clinic by the United States Food and Drug Administration.
Market Action
On Wednesday, TRNLY stock gained 7.18% to $3.4300 with more than 5K shares, compared to its average volume of 620 shares. The stock moved within a range of $3.4300 – 3.6100 after opening trading at $3.6100.
liberDi Receives FDA Regulatory Clearance for its Digital Dialysis System
The product in question is quite innovative in nature and allows people to perform dialysis on their own at home or at work. However, at the same time, the whole process is monitored by a physician thanks to the high tech telemedicine features that are on offer with the system.
The Chief Executive Officer of liberDi HezkiahTsoory spoke about the development as well and noted that the FDA clearance was a major new achievement for the company.
He went on to note that it was a major step in the company’s quest to improve the lives of people who may need dialysis on a regular basis. Considering the fact that the product had been cleared it is now going to be interesting to see if the The Trendlines Group, the parent company, sees any action in its stock over the course of the rest of the week.
Key Quote
liberDi CEO, Hezkiah Tsoory remarked, “Receiving FDA clearance for our state of the art Digital Dialysis Clinic technology, is a huge achievement for liberDi. This is a big step forward in liberDi’s journey to improve the quality of life of people on dialysis. liberDi’s system is designed to provide these patients with ease of use, freedom of movement, automatic catheter connection flush technology and patient monitoring, while performing their daily dialysis activities from the comfort of their home or workplace. liberDi frees people from spending half of their lives in dialysis centers, which is a disruptive technology in the dialysis market.”
 Stock Gains Momentum: Here is Why){kind=link}